Search Results

You are looking at 1 - 10 of 102 items for :

  • "bortezomib" x
Clear All
Full access

Paul G. Richardson, Jacob P. Laubach, Robert L. Schlossman, Constantine Mitsiades and Kenneth Anderson

, 23 although neurotoxicity can also occur with short-term exposure. Bortezomib-Induced PN (BiPN) Bortezomib-induced PN is predominantly a small-fiber sensory neuropathy, characterized by distal symmetric loss of all modalities in the lower

Full access

Jacob P. Laubach, Constantine S. Mitsiades, Anuj Mahindra, Marlise R. Luskin, Jacalyn Rosenblatt, Irene M. Ghobrial, Robert L. Schlossman, David Avigan, Noopur Raje, Nikhil C. Munshi, Kenneth C. Anderson and Paul G. Richardson

. Induction regimens that incorporate thalidomide, lenalidomide, and/or bortezomib are now standard for newly diagnosed MM in the United States. 8 – 12 Eligible patients may undergo autologous stem cell transplantation (ASCT), which deepens and prolongs the

Full access

Ashraf Z. Badros

from the start of maintenance was 53.1 months in the thalidomide/interferon arm and not yet reached in the interferon-alone arm ( P = .49). Data on bortezomib-based maintenance strategies are beginning to emerge. A randomized phase III trial

Full access

Jean-Luc Harousseau

Edited by Kerrin G. Robinson

Ferrero . Major shrinking of residual tumor cell burden and achievement of molecular remissions in myeloma patients undergoing post-transplant consolidation with bortezomib, thalidomide and dexamethasone: a qualitative and quantitative PCR study [abstract

Full access

Jean-Luc Harousseau and Philippe Moreau

2005 ; 106 : 35 – 39 . 23. Oakervee HE Popat R Curry N . PAD combination therapy (PS341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma . Br J Haematol 2005 ; 129 : 755 – 762 . 24

Full access

Jacob P. Laubach, Constantine S. Mitsiades, Anuj Mahindra, Robert L. Schlossman, Teru Hideshima, Dharminder Chauhan, Nicole A. Carreau, Irene M. Ghobrial, Noopur Raje, Nikhil C. Munshi, Kenneth C. Anderson and Paul G. Richardson

caspase-dependent downregulation of gp130 in multiple myeloma . Oncogene 2003 ; 22 : 8386 – 8393 . 79 von Metzler I Krebbel H Hecht M . Bortezomib inhibits human osteoclastogenesis . Leukemia 2007 ; 21 : 2025 – 2034 . 80

Full access

Ashraf Badros

, bortezomib, and lenalidomide may neutralize the effects of negative prognostic factors. An effective means of risk stratification is required so that patients with poor risk may be offered more aggressive treatment or be entered into clinical trials of novel

Full access

Ruben Niesvizky and Ashraf Z. Badros

Therapies such as thalidomide, bortezomib, and lenalidomide have provided meaningful benefits in multiple myeloma (MM), such as improved response rates and improved duration of response, but they have been associated with an increased risk of

Full access

Philip L. McCarthy

increased. 1 This improved OS is likely from the use of novel agents that improve PFS, including the immunomodulatory drugs (IMiDs) thalidomide 2 , 3 and lenalidomide, 4 - 7 and the proteasome inhibitor bortezomib. 8 - 13 These drugs, usually as part of

Full access

Kirsten Stuber, Habte A. Yimer, Karin Choquette, Sudhir Manda, Jennifer Clayton, Saulius Girnius, Joshua Richter, Presley Whidden, Kimberly Bogard, Dasha Cherepanov and Stephen J. Noga

Background: US MM-6 is evaluating in-class transition from parenteral bortezomib-based induction to all-oral IRd in US community NDMM pts, with the aim of increasing proteasome-inhibitor-based treatment duration while maintaining quality of life